Skip to content

Tablet

DRUG15 trials

Sponsors

Alumis Inc., Spero Therapeutics Inc., UZ Leuven, Imbria Pharmaceuticals Inc., Crinetics Pharmaceuticals Inc.

Conditions

AnxietyArthroplasty ComplicationsChronic Inducible Urticaria and Chronic Spontaneous UrticariaClassic Congenital Adrenal HyperplasiaClassic congenital adrenal hyperplasiaCognitive DisorderFearHealthy

Phase 2

Effects of Memantine to improve cognitive disorders caused by ECT in patients with major depressive disorder
Active, not recruitingIRCT201506203930N38
Shiraz University of Medical Sciences, Vice Chancellor for ResearchMajor depressive disorder. Depressive episode
Start: 2016-05-28Target: 40Updated: 2018-02-22
[M20-186] A Phase 2, Long-Term Extension (LTE) Study With Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599) in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus Who Have Completed the M19-130 Phase 2 Randomized Controlled Trial (RCT)
Active, not recruitingJPRN-jRCT2031210119
Otani TetsuyaSystemic Lupus Erythematosus
Start: 2021-04-27Target: 260Updated: 2025-07-18
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Dose Levels of ESK-001 in Adult Patients with Systemic Lupus Erythematosus
Active, not recruitingCTIS2022-502105-15-00
Alumis Inc.Systemic lupus erythematosus
Start: 2023-10-20Target: 136Updated: 2025-11-14
A Phase 2 Study to Evaluate the Safety, Tolerability, and Clinical Activity of BLU-808, a Wild Type KIT Inhibitor, in Chronic Inducible Urticaria and Chronic Spontaneous Urticaria
RecruitingCTIS2024-520031-33-00
Blueprint Medicines Corp.Chronic Inducible Urticaria and Chronic Spontaneous Urticaria
Start: 2025-09-16Target: 57Updated: 2025-09-05
A Global Phase 2b, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients with Symptomatic Non Obstructive Hypertrophic Cardiomyopathy – FORTITUDE-HCM
RecruitingCTIS2024-515125-28-00
Imbria Pharmaceuticals Inc.Non-obstructive hypertrophic cardiomyopathy
Start: 2025-12-08Target: 130Updated: 2025-12-05
A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants with Congenital Adrenal Hyperplasia Including a Long-Term Extension
Not yet recruitingCTIS2024-519578-38-00
Crinetics Pharmaceuticals Inc.Classic congenital adrenal hyperplasia
Target: 61Updated: 2026-01-07

Phase 3

Phase 4

Unknown Phase